Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1958 1
1959 1
1961 1
1962 1
1963 3
1964 1
1965 4
1966 3
1967 3
1968 5
1969 2
1970 11
1971 8
1972 17
1973 9
1974 11
1975 24
1976 19
1977 27
1978 40
1979 32
1980 39
1981 48
1982 49
1983 72
1984 88
1985 91
1986 104
1987 94
1988 87
1989 100
1990 134
1991 130
1992 151
1993 142
1994 122
1995 153
1996 128
1997 155
1998 176
1999 170
2000 188
2001 203
2002 219
2003 228
2004 229
2005 307
2006 282
2007 305
2008 338
2009 389
2010 412
2011 462
2012 479
2013 548
2014 652
2015 738
2016 742
2017 780
2018 815
2019 915
2020 1024
2021 1210
2022 1050
2023 943
2024 381

Text availability

Article attribute

Article type

Publication date

Search Results

14,404 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Pulmonary fibrosis and/or bone marrow failure, Telomere-related, 3"
Page 1
Progressive pulmonary fibrosis: an expert group consensus statement.
Rajan SK, Cottin V, Dhar R, Danoff S, Flaherty KR, Brown KK, Mohan A, Renzoni E, Mohan M, Udwadia Z, Shenoy P, Currow D, Devraj A, Jankharia B, Kulshrestha R, Jones S, Ravaglia C, Quadrelli S, Iyer R, Dhooria S, Kolb M, Wells AU. Rajan SK, et al. Eur Respir J. 2023 Mar 30;61(3):2103187. doi: 10.1183/13993003.03187-2021. Print 2023 Mar. Eur Respir J. 2023. PMID: 36517177 Free PMC article. Review.
The value of diagnostic tests in risk stratification at presentation and, separately, the importance of a logical monitoring strategy, tailored to manage the risk of progression, are also stressed. The term "progressive pulmonary fibrosis" (PPF) exactly describes th …
The value of diagnostic tests in risk stratification at presentation and, separately, the importance of a logical monitoring strategy, tailo …
Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis.
Meyer KC. Meyer KC. Expert Rev Respir Med. 2017 May;11(5):343-359. doi: 10.1080/17476348.2017.1312346. Epub 2017 Apr 10. Expert Rev Respir Med. 2017. PMID: 28345383 Review.
Many forms of interstitial lung disease (ILD) can progress to extensive fibrosis and respiratory failure. Idiopathic pulmonary fibrosis (IPF), which generally has a poor prognosis, has been thoroughly studied over the past two decades, and many importa …
Many forms of interstitial lung disease (ILD) can progress to extensive fibrosis and respiratory failure. Idiopathic pulmon …
Idiopathic pulmonary fibrosis: Epithelial-mesenchymal interactions and emerging therapeutic targets.
Hewlett JC, Kropski JA, Blackwell TS. Hewlett JC, et al. Matrix Biol. 2018 Oct;71-72:112-127. doi: 10.1016/j.matbio.2018.03.021. Epub 2018 Apr 3. Matrix Biol. 2018. PMID: 29625182 Free PMC article. Review.
Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic disease of the lung that is marked by progressive decline in pulmonary function and ultimately respiratory failure. ...This review provides an overview of the interactions of the pathogenic mech …
Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic disease of the lung that is marked by progressive decline in pulm …
Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis.
Strykowski R, Adegunsoye A. Strykowski R, et al. Immunol Allergy Clin North Am. 2023 May;43(2):209-228. doi: 10.1016/j.iac.2023.01.010. Epub 2023 Mar 3. Immunol Allergy Clin North Am. 2023. PMID: 37055085 Review.
Idiopathic pulmonary fibrosis (IPF), a common interstitial lung disease (ILD), is a chronic, progressive fibrosing interstitial pneumonia, with an unknown cause. ...Patients with ILD other than IPF, and who have radiological evidence of pulmonary fibrosis …
Idiopathic pulmonary fibrosis (IPF), a common interstitial lung disease (ILD), is a chronic, progressive fibrosing interstitia …
Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases.
Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaola M, Skowasch D, Park JS, Poonyagariyagorn HK, Wuyts W, Wells AU. Cottin V, et al. Eur Respir Rev. 2018 Dec 21;27(150):180076. doi: 10.1183/16000617.0076-2018. Print 2018 Dec 31. Eur Respir Rev. 2018. PMID: 30578335 Free PMC article. Review.
Although these conditions are rare, a proportion of patients with interstitial lung diseases (ILDs) may develop a progressive-fibrosing phenotype. Progressive fibrosis is associated with worsening respiratory symptoms, lung function decline, limited response to immunomodul …
Although these conditions are rare, a proportion of patients with interstitial lung diseases (ILDs) may develop a progressive-fibrosing phen …
Pulmonary hypertension in chronic lung diseases.
Seeger W, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galiè N, Ghio S, Gibbs S, Martinez FJ, Semigran MJ, Simonneau G, Wells AU, Vachiéry JL. Seeger W, et al. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D109-16. doi: 10.1016/j.jacc.2013.10.036. J Am Coll Cardiol. 2013. PMID: 24355635 Free article. Review.
Chronic obstructive lung disease (COPD) and diffuse parenchymal lung diseases (DPLD), including idiopathic pulmonary fibrosis (IPF) and sarcoidosis, are associated with a high incidence of pulmonary hypertension (PH), which is linked with exercise limitation …
Chronic obstructive lung disease (COPD) and diffuse parenchymal lung diseases (DPLD), including idiopathic pulmonary fibrosis …
Pulmonary fibrosis secondary to COVID-19: a narrative review.
Tanni SE, Fabro AT, de Albuquerque A, Ferreira EVM, Verrastro CGY, Sawamura MVY, Ribeiro SM, Baldi BG. Tanni SE, et al. Expert Rev Respir Med. 2021 Jun;15(6):791-803. doi: 10.1080/17476348.2021.1916472. Epub 2021 Apr 27. Expert Rev Respir Med. 2021. PMID: 33902377 Review.
Therefore, serial clinical, tomographic, and functional screening for pulmonary fibrosis is recommended after COVID-19, mainly in patients with pulmonary involvement in the acute phase of the disease. Further studies are necessary to determine the risk factor …
Therefore, serial clinical, tomographic, and functional screening for pulmonary fibrosis is recommended after COVID-19, mainly …
Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP, Ponnuswamy A, Dutta P, Abdelaziz A, Kamil H. Finnerty JP, et al. BMC Pulm Med. 2021 Dec 11;21(1):411. doi: 10.1186/s12890-021-01783-1. BMC Pulm Med. 2021. PMID: 34895203 Free PMC article.
BACKGROUND: Research questions To compare the efficacy of nintedanib and pirfenidone in the treatment of progressive pulmonary fibrosis; and to compare the efficacy of anti-fibrotic therapy (grouping nintedanib and pirfenidone together) in patients with IPF versus p …
BACKGROUND: Research questions To compare the efficacy of nintedanib and pirfenidone in the treatment of progressive pulmonary fib …
Molecular pathways and role of epigenetics in the idiopathic pulmonary fibrosis.
Velagacherla V, Mehta CH, Nayak Y, Nayak UY. Velagacherla V, et al. Life Sci. 2022 Feb 15;291:120283. doi: 10.1016/j.lfs.2021.120283. Epub 2022 Jan 5. Life Sci. 2022. PMID: 34998839 Review.
Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with unknown etiological factors that can progress to other dangerous diseases like lung cancer. ...Gefitinib, a tyrosine kinase inhibitor of EGFR, is useful as an anti-fibrosis agent in preclinical …
Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with unknown etiological factors that can progress to other danger …
Fibrosing interstitial lung diseases: knowns and unknowns.
Cottin V, Wollin L, Fischer A, Quaresma M, Stowasser S, Harari S. Cottin V, et al. Eur Respir Rev. 2019 Feb 27;28(151):180100. doi: 10.1183/16000617.0100-2018. Print 2019 Mar 31. Eur Respir Rev. 2019. PMID: 30814139 Free PMC article. Review.
Patients with certain types of fibrosing interstitial lung disease (ILD) are at risk of developing a progressive phenotype characterised by self-sustaining fibrosis, decline in lung function, worsening quality of life, and early mortality. ...At present, no drugs are appro …
Patients with certain types of fibrosing interstitial lung disease (ILD) are at risk of developing a progressive phenotype characterised by …
14,404 results
You have reached the last available page of results. Please see the User Guide for more information.